Identification of potential Staphylococcus aureus dihydrofolate reductase inhibitors using QSAR, molecular docking, dynamics simulations and free energy calculation.
Isaac de Araujo MatosAna Carolina Goes PintoMatheus Vitor Ferreira FerrazWenny Camilla Santos AdanRicardo Pereira RodriguesJuliane Xavier Dos SantosRodrigo Rezende Kitagawanull Roberto Dias LinsTiago Branquinho OliveiraNivan Bezerra da Costa JuniorPublished in: Journal of biomolecular structure & dynamics (2022)
Herein we describe the use of molecular docking simulations, quantitative structure-activity relationships studies and ADMETox predictions to analyse the molecular recognition of a series of 7-aryl-2,4-diaminoquinazoline derivatives on the inhibition of Staphylococcus aureus dihydrofolate reductase and conducted a virtual screening to discover new potential inhibitors. A quantitative structure-activity relationship model was developed using 40 compounds and two selected descriptors. These descriptors indicated the importance of pKa and molar refractivity for the inhibitory activity against Sa DHFR. The values of R 2 train , CV LOO and R 2 test generated by the model were 0.808, 0.766, and 0.785, respectively. The integration between QSAR, molecular docking, ADMETox analysis and molecular dynamics simulations with binding free energies calculation, yielded the compounds PC-124127620, PC-124127795 and PC-124127805 as promising candidates to Sa DHFR inhibitors. These compounds presented high potency, good pharmacokinetics and toxicological profile. Thus, these molecules are good potential antimicrobial agent to treatment of infect disease caused by S. aureus .Communicated by Ramaswamy H. Sarma.
Keyphrases
- molecular docking
- molecular dynamics simulations
- staphylococcus aureus
- structure activity relationship
- monte carlo
- high resolution
- molecular dynamics
- biofilm formation
- methicillin resistant staphylococcus aureus
- risk assessment
- density functional theory
- transcription factor
- climate change
- combination therapy
- replacement therapy
- candida albicans